CENTOCOR, INC.
🇺🇸United States
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CNTO 328 (Sp2/0-derived)Drug: CNTO 328 (CHO-derived)Drug: Placebo
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT02074800
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01362153
A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01288157
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 3
Withdrawn
- Conditions
- Multiple Myeloma
- Interventions
- Biological: Siltuximab, Velcade and dexamethasoneDrug: Placebo, Velcade and dexamethasone
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Centocor, Inc.
- Registration Number
- NCT01266811
A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: 200 mg golimumab or placeboDrug: 400 mg golimumab or placebo
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01258777
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis
Phase 3
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT01248793
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT01248780
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: CNTO888 + docetaxelDrug: CNTO888 + gemcitabineDrug: CNTO888 + Paclitaxel and carboplatinDrug: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT01204996
A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Biological: CNTO 3157 or placebo
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT01195207
A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: CNTO 5825
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01081691
© Copyright 2025. All Rights Reserved by MedPath